1
|
Solé S, Becerra S, Carvajal C, Bettolli P, Letelier H, Santini A, Vargas L, Cifuentes A, Larsen F, Jara N, Oyarzún J, Bustamante E, Martínez B, Rosenberg D, Galván T. Clinical relevance of the use of Dentoxol ® for oral mucositis induced by radiotherapy: A phase II clinical trial. World J Clin Oncol 2022; 13:813-821. [PMID: 36337310 PMCID: PMC9630999 DOI: 10.5306/wjco.v13.i10.813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 07/22/2022] [Accepted: 09/21/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Severe oral mucositis associated with cancer therapy is a frequent complication that may affect a patient's systemic condition, resulting in interruption and/or prolongation of cancer therapy. Dentoxol® is a medical solution in the form of a mouthwash that has been shown to result in statistically significant improvement in the prevention of severe oral mucositis. However, knowing the measures of the clinical significance of this therapy is important for accurate decision-making.
AIM To describe the clinical impact of Dentoxol® use in severe oral mucositis.
METHODS Clinical significance was measured using the results obtained in a randomized controlled clinical trial previously conducted by the same group of researchers. The measures of clinical significance evaluated were the absolute risk or incidence, relative risk, absolute risk reduction, relative risk reduction, number needed to treat, and odds ratio.
RESULTS The data obtained show that the impact of Dentoxol® on reducing the severity of oral mucositis has important clinical relevance.
CONCLUSION The results of this study justify the incorporation of Dentoxol® mouth rinse into clinical protocols as a complement to cancer therapy to prevent and/or treat oral mucositis secondary to radiotherapy.
Collapse
Affiliation(s)
- Sebastián Solé
- Department of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile
| | - Sergio Becerra
- National Institute of Cancer, Santiago, Servicio de Salud Metropolitano Norte, Av Profesor Zañartu 1010, Independencia, 8380455, Santiago, Chile
| | - Claudia Carvajal
- National Institute of Cancer, Santiago, Servicio de Salud Metropolitano Norte, Av Profesor Zañartu 1010, Independencia, 8380455, Santiago, Chile
| | - Piero Bettolli
- Oncologic Institute Arturo López Pérez Foundation, José Manuel Infante 805, Providencia, 7500691, Santiago, Chile
| | - Hernán Letelier
- Hospital Base Valdivia, Bueras 1003 s/n XIV Región, 5100238, Valdivia, Chile
| | - Alejandro Santini
- Oncologic Center of Antofagasta, Los Pumas 10255, Antofagasta, 1267348, Antofagasta, Chile
| | - Lorena Vargas
- Department of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile
| | - Alexander Cifuentes
- National Institute of Cancer, Santiago, Servicio de Salud Metropolitano Norte, Av Profesor Zañartu 1010, Independencia, 8380455, Santiago, Chile
| | - Francisco Larsen
- Department of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile
| | - Natalia Jara
- Department of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 7630370, Santiago, Chile
| | - Jorge Oyarzún
- Hospital Base Valdivia, Bueras 1003 s/n XIV Región, 5100238, Valdivia, Chile
| | - Eva Bustamante
- Oncologic Institute Arturo López Pérez Foundation, José Manuel Infante 805, Providencia, 7500691, Santiago, Chile
| | - Benjamín Martínez
- Universidad Mayor, Santiago, Av Libertador Bernardo O´Higgins 2013, 8340585, Santiago, Chile
| | - David Rosenberg
- Ingalfarma, Dr Manuel Barros Borgoño 71, Oficina 1308, Providencia, 7500593, Santiago, Chile
| | - Tomas Galván
- Ingalfarma, Dr Manuel Barros Borgoño 71, Oficina 1308, Providencia, 7500593, Santiago, Chile
| |
Collapse
|